Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders (2016 - 2025)

Cumberland Pharmaceuticals' Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 32.42% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached -$2.5 million, up 58.95%, while the annual FY2025 figure was -$2.5 million, 59.03% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$1.1 million at Cumberland Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.2 million in Q1 2025 and bottomed at -$1.9 million in Q3 2025.
  • The 4-year median for Net Income towards Common Stockholders is -$735207.0 (2025), against an average of -$426225.4.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 1204.25% in 2024 before it skyrocketed 165.61% in 2025.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at $503318.0 in 2021, then tumbled by 311.24% to -$1.1 million in 2023, then plummeted by 50.18% to -$1.6 million in 2024, then surged by 32.42% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Net Income towards Common Stockholders are -$1.1 million (Q4 2025), -$1.9 million (Q3 2025), and -$735207.0 (Q2 2025).